John Chabot, MD, chief, division of GI/Endocrine Surgery, executive director, Pancreas Center at New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, discusses the current chemotherapy options available to treat pancreatic cancer. The main drug available is gemcitabine
and is currently used in combination therapies.
There are currently trials underway that are demonstrating improved survival with aggressive chemotherapy. Nongemcitabine regiment was identified that proved to be a better treatment option for stage IV pancreatic cancer than gemcitabine. Chabot expects that drugs that are used in other types of cancer will show the most significant improvement in the future.